title: The parkinsonism-hyperpyrexia syndrome.
abstract: The parkinsonism-hyperpyrexia syndrome (PHS) is a rare but potentially fatal complication seen in Parkinson's disease (PD) patients, most commonly following reduction or cessation of antiparkinson medications. Clinically it resembles neuroleptic malignant syndrome with rigidity, pyrexia, and reduced conscious level. There may be features of autonomic instability, and serum creatine kinase (CK) may be elevated. Complications of PHS include acute renal failure, aspiration pneumonia, deep venous thrombosis/pulmonary embolism, and disseminated intravascular coagulation (DIC). Management consists of dopaminergic drug replacement, supportive measures, and treatment of complications. The prognosis is improved with early recognition and management. Mortality of up to 4% has been reported, but an additional one-third of patients have permanent sequelae. Patients and physicians should be warned against sudden reduction in antiparkinson medications. PHS should always be considered in a patient with parkinsonism who presents with an acute deterioration in symptoms.
authors: Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, G51 4TF, UK.
authors: Edward J
authors: EJ
authors: Newman
authors: Donald G
authors: DG
authors: Grosset
authors: Peter G E
authors: PG
authors: Kennedy
mesh_terms: D000978:Antiparkinson Agents / Q000009:adverse effects; D017809:Fatal Outcome; D006801:Humans; D008297:Male; D008305:Malignant Hyperthermia / Q000175:diagnosis* / Q000209:etiology / Q000503:physiopathology; D008875:Middle Aged; D020734:Parkinsonian Disorders / Q000175:diagnosis* / Q000209:etiology / Q000503:physiopathology; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology; D013577:Syndrome
chemical_list: D000978:Antiparkinson Agents